Plasmodium cytochrome bc1 complex (None standard; commonly referred to as cytochrome bc1 or Complex III in mitochondrial literature)

The Plasmodium cytochrome bc1 complex (Complex III) is an intrinsic mitochondrial membrane enzyme essential for electron transport and ATP generation in Plasmodium species, including the malaria parasite Plasmodium falciparum. It catalyzes the oxidation of ubihydroquinone and reduction of cytochrome c via the Q-cycle, facilitating the proton gradient needed for ATP synthesis. This complex is a proven and validated antimalarial drug target. Drugs such as atovaquone and 4(1H)-pyridones act by binding to the Qo or Qi sites, blocking mitochondrial function and leading to parasite death. The enzyme’s structure and drug-binding sites have been elucidated, enabling development of novel inhibitors and providing insight into drug resistance mechanisms. Selectivity over host Complex III and the risk of resistance are critical challenges in therapeutic applications. The cytochrome bc1 complex plays no direct signaling role but is vital for the parasite’s energy metabolism and survival during infection.

Other names

Mitochondrial respiratory chain Complex IIICytochrome bc1 complexCyt bc1Complex III

Inhibition of mitochondrial electron transport at the Qo (ubiquinol oxidation) or Qi (ubiquinone reduction) site, halting ATP synthesis and parasite energy metabolism Induction of metabolic collapse within the parasite due to loss of mitochondrial function